PCSK9 inhibitors -- alirocumab (Praluent), evolocumab (Repatha), and inclisiran (Leqvio) -- are injections that keep LDL receptors free to bind to LDL cholesterol and keep it out of the blood ...

Evolocumab (Repatha) was approved for children ages 10 and older with heterozygous and homozygous FH based on a trial showing a 38.3 percentage point greater reduction in LDL cholesterol over 24 ...

This study has the purpose to answer how the Lipoprotein (a) (Lp (a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between ...

This narrative review discusses the genetic determinants of plasma lipoprotein(a) levels and explores the factors that influence interindividual heterogeneity, including single‐nucleotide ...

Evolocumab treatment significantly decreased proinflammatory cytokine expression (IL-1β, HMGB1, IL-6,&TNFα) in aortic tissue compared to untreated controls in both models and was associated with less ...

IMPORTANT SAFETY INFORMATION Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®.

New Repatha® Data Provide Insight Into the Benefits of Lipid Lowering Therapy in People With Type 1 Diabetes Amgen to Host Investor Webcast on MariTide Data on June 23 at 4:30 p.m. CDT ...